Rexahn reports Q4 total operating expense $8M Rexahn’s Q4 cash and investments totaled $19.M vs $14.7M last year. The company said the increase of $4.3M was primarily due to $12.3M from the issuance of common stock and the exercise of stock warrants and options, offset by $8M of net cash used in operating activities.
Rexahn announces positive preclinical data on Supinoxin Rexahn announced that it presented preclinical data on Supinoxin at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia. In the present study, Supinoxin was shown to dose-dependently decrease the migration of human triple negative breast cancer cells in a preclinical model of cancer cell metastasis. Supinoxin is currently in a Phase I dose-escalation clinical trial in cancer patients with solid tumors with clinical data expected in the first half of 2015.